DrugPatentWatch Database Preview

Details for Patent: 7,511,041

« Back to Dashboard

Which drugs does patent 7,511,041 protect, and when does it expire?

Patent 7,511,041 protects ALIQOPA and is included in one NDA.

This patent has fifty patent family members in thirty-two countries.

Summary for Patent: 7,511,041

Title:	Fused azole-pyrimidine derivatives
Abstract:	The present invention relates to hovel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidylinositol-3-kinase (PI3K) inhibition, especially for PI3K-.gamma. inhibition and can be used for the prophylaxis and treatment of diseases associated with PI3K and particularly with PI3K-.gamma. activity. More specifically, the azole derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, autoixnmune pathologies such as rheumatoid arthritis, and Graves' disease, cancer, myocardial contractility disorders, heart failure, thromboembolism, ischemia, and atherosclerosis. The compounds of the present invention are also useful for pulmonary hypertension, renal failure, cardiac hypertrophy, as well as neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, diabetes and focal ischemia, since the diseases also relate to PI3K activity in a human or animal subject.
Inventor(s):	Shimada; Mitsuyuki (Nara, JP), Murata; Toshiki (Nara, JP), Fuchikami; Kinji (Tokyo, JP), Tsujishita; Hideki (Kyoto, JP), Omori; Naoki (Hyogo, JP), Kato; Issei (Nara, JP), Miura; Mami (Nara, JP), Urbahns; Klaus (Lund, SE), Gantner; Florian (Constance, DE), Bacon; Kevin (San Diego, CA)
Assignee:	Bayer Pharmaceuticals Corporation (West Haven, CT)
Application Number:	10/527,376
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 7,511,041

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bayer Healthcare	ALIQOPA	copanlisib dihydrochloride	POWDER;INTRAVENOUS	209936-001	Sep 14, 2017		RX	Yes	Yes			Y	Y

Foreign Priority and PCT Information for Patent: 7,511,041

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	02021861	Sep 30, 2002

PCT Information
PCT Filed	September 18, 2003	PCT Application Number:	PCT/EP03/10377
PCT Publication Date:	April 08, 2004	PCT Publication Number:	WO2004/029055

International Family Members for US Patent 7,511,041

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	041426
Argentina	072458
Austria	411996
Austria	511510
Australia	2003293310
Brazil	0314830
Brazil	PI0314830